Navigation Links
Resverlogix Completes Dosing for ASSERT Trial
Date:5/12/2010

Completion occurs 5 months ahead of schedule

TSX Exchange Symbol: RVX

CALGARY, May 12 /PRNewswire-FirstCall/ - Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug. Our clinical team and our collaborators at the Cleveland Clinic will now spend the next few months assessing the study results to best plan for upcoming trials. The swift completion of the ASSERT study further allows us to make better assessments in identifying optimal dosing regimens moving forward," explained Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey continued, "Earlier studies have indicated that the drug worked best in those subjects with low HDL, therefore we will further assess if RVX-208 has a targeted effect in this high risk cardiovascular disease population. The rapid enrollment and dosing success for this trial was in large part due to having one organized Internal Review Board (IRB) for all 40 sites involved in the trial."

The ASSERT trial is a randomized, double-blind, placebo-controlled, multi-centered US study for 13 weeks of administration of RVX-208, which has enrolled 299 patients with stable coronary artery disease for a period of 13 weeks. The primary endpoint of the study is to determine if RVX-208 will produce an increase in plasma Apolipoprotein A-I (ApoA-I) levels compared to placebo group after three months of dosing. Other objectives are to examine the safety and tolerability of RVX-208 and to com
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 NANONEX CORPORATION, a pioneer ... today announced the successful delivery and installation of ... NX-M200B, to a major Japanese manufacturing company. ... production-ready, advanced nanoimprint lithography tool that has the ... substrate sizes and types. Based on Nanonex inventions ...
(Date:5/21/2013)... May 21, 2013 Possible mold re-infestation in ... according to a report from eagletribune.com posted May 14, 2013, ... case the result is positive, My Cleaning Products offered a ... chemical ingredients. , It was said in the Eagle Tribune ... in the campus sparked after a first-grade classroom was closed ...
(Date:5/21/2013)... The Formulate Fusion Fabric Display Kit ... marketing teams looking for a fully-functional package for their trade ... you’ll need to put together a stunning and eye-catching trade ... number of displays and accessories that can be quickly assembled ... feet in size. These components vary from kit to kit, ...
(Date:5/20/2013)... 21, 2013 Grace Century , ... “game-changing” life science and health related private equity projects, ... its International Project Team. Dergham's expertise in finance and ... depth to Grace Century as it continues to look ... Ms. Dergham holds both an under graduate degree from ...
Breaking Biology Technology:Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Dalia Dergham Joins Grace Century FZ LLC International Project Team 2
... Adhere to Sleep Apnea TreatmentSAN CARLOS, Calif., Feb. ... study has shown their patients comply with Obstructive ... the industry average.Analysis performed in October 2008 looked ... testing and treatment with Positive Airway Pressure beginning ...
... 3 BioMarin Pharmaceutical Inc. (Nasdaq: ... 2 multi-center, randomized, double-blind, placebo-controlled clinical study of ... (PAD). There was no statistical significance observed ... endpoint of the study, peak walking time (PWT), ...
... Bulletin Board: AGGX.OB) is a New York-based biotechnology company ... proteins for the discovery and development of anti-angiogenic drugs ... presented animal data at two recent scientific ... molecule candidate drug AGX51 to mitigate tumor formation and ...
Cached Biology Technology:SleepQuest Compliance Again Doubles Industry Average 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 3Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 4AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 2AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 3
(Date:5/20/2013)... effect of physical education (PE) on child weight, but ... the amount of time that elementary schoolchildren spent in ... study represents some of the first evidence of a ... forthcoming in the Journal of Health Economics . ... be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The research ...
(Date:5/20/2013)... (May 20, 2013) - A novel vaccine ... the groundbreaking research that will be unveiled at the ... (NBC). The meeting takes place Monday, May 20 - ... and Marina. , "The main goal of a ... against a pathogen that causes the disease", explained Dr. ...
(Date:5/19/2013)... have engineered a strain of electricity-producing bacteria that can ... and carbon dioxide as its sole source of carbon. ... their findings at the 113th General Meeting of the ... result of current production solely on hydrogen," says Amit ... his co-authors are part of the Lovley Lab Group ...
Breaking Biology News(10 mins):Gym class reduces probability of obesity, study finds for first time 2Germ-fighting vaccine system makes great strides in delivery 2
... days shortening toward winter, many people will begin to experience ... About 6 percent of the U.S. population suffers ... begins in the fall and continues through winter. Sufferers may ... the morning. The disorder, which is not well understood, ...
... look at that cheap piece of scrap iron before you ... good use for it. Someday soon, much of the world ... engineering, recently concluded a five-year research project in which he ... million pounds of iron to detoxify pollutants in industrial wastewater. ...
... and simulation experts from Rhode Island Hospital discuss ... manuscripts appearing in the November 2008 issue of ... The articles describe how simulation centers, along with ... for dynamic, complex and unanticipated medical situations in ...
Cached Biology News:Seasonal affective disorder may be linked to genetic mutation, study suggests 2A green future for scrap iron 2A green future for scrap iron 3Rhode Island Hospital simulation center examines benefits and applications of medical simulation 2Rhode Island Hospital simulation center examines benefits and applications of medical simulation 3
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... The steadylite plus assay ... High assay sensitivity, Designed for ... Suitable for higher density microplates ... plates, Odor free, Convenient storage ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Functionally tested for consistent G-banding of chromosomes....
Biology Products: